Zhong Peng-Yu, Sun Bin, Cao Hai-Ping, Wang Wei, Xiong Ting-Lin
Department of Cardiology, Nanchong Central Hospital (Nanchong Hospital of Beijing Anzhen Hospital/The Second Clinical College of North Sichuan Medical College), 637000 Nanchong, Sichuan, China.
Rev Cardiovasc Med. 2024 Jun 4;25(6):209. doi: 10.31083/j.rcm2506209. eCollection 2024 Jun.
Percutaneous coronary intervention is the main strategy of revascularization and has been shown to improve outcomes in some patients with ST-segment elevation myocardial infarction (STEMI). However, multivessel disease (MVD), a common condition in these patients, is associated with worse clinical outcomes compared to single-vessel disease. Despite intervention being a standard treatment for coronary artery disease, optimal strategies and timings for patients with STEMI and MVD remain unclear. Numerous studies and meta-analyses have investigated this topic; however, many current conclusions are based on observational studies. Furthermore, clinical guidelines regarding the management of patients with STEMI and MVD contain conflicting recommendations. Therefore, we aimed to compile relevant studies and newly available evidence-based medicines to explore the most effective approach.
经皮冠状动脉介入治疗是血运重建的主要策略,已被证明可改善部分ST段抬高型心肌梗死(STEMI)患者的预后。然而,多支血管病变(MVD)在这些患者中较为常见,与单支血管病变相比,其临床预后更差。尽管介入治疗是冠状动脉疾病的标准治疗方法,但STEMI合并MVD患者的最佳治疗策略和时机仍不明确。众多研究和荟萃分析对这一主题进行了调查;然而,许多当前的结论是基于观察性研究得出的。此外,关于STEMI合并MVD患者管理的临床指南包含相互矛盾的建议。因此,我们旨在汇总相关研究和新出现的循证药物,以探索最有效的方法。